1
Toufike Kanouni
Qing Dong, Xianchang Gong, Stephen W Kaldor, Toufike Kanouni, Nicholas Scorah, Michael B Wallace, Feng Zhou: MAPK/ERK KINASE INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY, TAKEDA SAN DIEGO, May 27, 2010: US20100130518-A1

Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of usin ...


2
Toufike Kanouni
Qing Dong, Xianchang Gong, Stephen W Kaldor, Toufike Kanouni, Nicholas Scorah, Michael B Wallace, Feng Zhou: Mapk/erk kinase inhibitors. Takeda San Diego, October 16, 2008: US20080255160-A1

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


3
Toufike Kanouni
MarK Adams, Qing Dong, Toufike Kanouni, Stephen W Kaldor, Nicholas Scorah, Michael B Wallace: Mapk/erk kinase inhibitors. Takeda Pharmaceutical Company, Takeda San Diego, May 14, 2009: US20090124595-A1

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


4
Bruce A Dressman, James E Fritz, Marlys Hammond, William J Hornback, Stephen W Kaldor, Vincent J Kalish, John E Munroe, Siegfried H Reich, John H Tatlock, Timothy A Shepherd, Michael J Rodriguez: HIV protease inhibitors. Agouron Pharmaceuticals, Finnegan Henderson Farabow Garrett & Dunner, January 16, 1996: US05484926 (59 worldwide citation)

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral ...


5

6
Bruce A Dressman, James E Fritz, Marlys Hammond, William J Hornback, Stephen W Kaldor, Vincent J Kalish, John E Munroe, Siegfried Heinz Reich, John H Tatlock, Timothy A Shepherd, Michael J Rodriguez: HIV protease inhibtors. Agouron Pharmaceuticals, Finnegan Henderson Farabow Garrett & Dunner L, October 27, 1998: US05827891 (15 worldwide citation)

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral ...


7
Jun Feng, Stephen L Gwaltney II, Stephen W Kaldor, Jeffrey A Stafford, Michael B Wallace, Zhiyuan Zhang: Dipeptidyl peptidase inhibitors. Takeda Pharmaceutical Company, Michell R Brustein, December 30, 2008: US07470700 (13 worldwide citation)

Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.


8
James E Fritz, Marlys Hammond, Stephen W Kaldor: Inhibitors of HIV protease. Eli Lilly and Company, Janet T McClain, Gerald V Dahling, July 18, 1995: US05434265 (12 worldwide citation)

The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating HIV infection.


9
James E Fritz, Marlys Hammond, Stephen W Kaldor: Intermediates for preparing HIV protease inhibitors. Eli Lilly and Company, Janet T McClain, May 7, 1996: US05514802 (11 worldwide citation)

The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.


10
Stephen W Kaldor, Marlys Hammond: Retroviral protease inhibitors. Eli Lilly and Company, Janet T McClain, April 16, 1996: US05508407 (11 worldwide citation)

The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of their use.